What are the indications, dosing regimens, contraindications, monitoring requirements, adverse effects, and alternative therapies for naltrexone in the treatment of opioid dependence and alcohol use disorder?

Naltrexone: Comprehensive Clinical Guide

Indications

Naltrexone is FDA-approved for two primary indications: alcohol use disorder and opioid use disorder, functioning as a competitive mu-opioid receptor antagonist that blocks euphoric effects of opioids and reduces alcohol cravings. 1, 2

Alcohol Use Disorder

• Naltrexone reduces alcohol craving and consumption by blocking opioid receptors and dampening activation of the reward pathway by alcohol, thereby decreasing excessive drinking and increasing abstinence duration 1, 3
• Moderate quality evidence supports naltrexone's effectiveness in reducing relapse to heavy drinking, though it is less effective in enhancing complete abstinence 1, 4
• The effect size is modest (0.15 to 0.2 range), but clinically meaningful when combined with psychosocial interventions 4

Opioid Use Disorder

• Naltrexone is most beneficial for highly motivated patients who cannot or do not wish to take continuous opioid agonist therapy (buprenorphine/methadone) 1, 3
• It has been shown particularly helpful in maintaining abstinence in motivated populations such as healthcare professionals 1, 3
• Naltrexone represents a second-line option after buprenorphine or methadone maintenance therapy, which have stronger evidence for preventing relapse 1

Off-Label Considerations

• Naltrexone-bupropion combination may be considered for patients with moderate or severe methamphetamine use disorder when behavioral therapies alone are insufficient, though no pharmacologic treatment for stimulant dependence can be recommended as monotherapy 5

---

Dosing Regimens

Oral Naltrexone

Standard dosing is 50 mg once daily, with alternative flexible regimens of 100 mg on Mondays and Wednesdays, and 150 mg on Fridays. 1, 3, 2

• Treatment should be initiated with 25 mg to assess tolerance, then increased to 50 mg daily if no withdrawal signs occur 2
• For alcohol dependence, the FDA-approved regimen used in efficacy trials was 50 mg once daily for up to 12 weeks 2
• A dose of 50 mg once daily produces adequate clinical blockade of parenterally administered opioids 2

Injectable Extended-Release Naltrexone (Vivitrol)

• 380 mg intramuscular injection administered monthly 1, 3
• Provides reliable naltrexone release over 1 month at therapeutic levels with significantly improved medication compliance compared to daily oral dosing 3, 6
• FDA-approved for both alcohol and opioid dependence 1

Dose Adjustments

• Patients with moderate-to-severe renal impairment should have their total daily dose reduced by one-half (25 mg daily) 1
• Patients with moderate-to-severe hepatic impairment should not exceed 25 mg daily 1

---

Contraindications

Absolute Contraindications

Patients must be completely opioid-free for a minimum of 7-10 days for short-acting opioids before starting naltrexone to avoid precipitating severe, potentially life-threatening withdrawal. 1, 3, 2

• Active opioid use or current opioid dependence 1, 5
• Patients requiring opioids for pain control, as naltrexone blocks pain relief from opioid agonists and causes precipitated withdrawal 1, 3
• Acute hepatitis or decompensated cirrhosis 1, 5
• Pregnancy (for opioid use disorder; offer buprenorphine or methadone instead) 1

Special Populations Requiring Extended Opioid-Free Period

• Patients transitioning from buprenorphine or methadone may be vulnerable to precipitation of withdrawal symptoms for as long as 2 weeks 2
• Healthcare providers should be prepared to manage withdrawal symptomatically with non-opioid medications 2

Relative Contraindications

• Compensated cirrhosis or moderate hepatic impairment requires case-by-case assessment, considering alternative medications like baclofen or acamprosate 1
• Patients with epilepsy or history of seizures (particularly for naltrexone-bupropion combination) 1

---

Pre-Treatment Requirements

Naloxone Challenge Test

The naloxone challenge test should be performed if there is any question of occult opioid dependence, but should NOT be performed in patients showing clinical signs of opioid withdrawal or whose urine contains opioids. 2

Intravenous Method:

• Inject 0.2 mg naloxone, observe for 30 seconds for withdrawal signs 2
• If no evidence of withdrawal, inject 0.6 mg naloxone and observe for an additional 20 minutes 2

Subcutaneous Method:

• Administer 0.8 mg naloxone and observe for 20 minutes for signs or symptoms of withdrawal 2

Interpretation:

• Monitor for withdrawal signs including nausea, vomiting, dysphoria, yawning, sweating, tearing, rhinorrhea, craving for opioids, abdominal cramps, pupillary dilation, changes in vital signs, anxiety, muscle aches, or tremors 2
• If test is positive, do NOT initiate naltrexone and repeat challenge in 24 hours 2
• If test is negative, naltrexone therapy may be started if no other contraindications are present 2

Baseline Assessments

• Screen for depression, anxiety, and insomnia before initiation, as naltrexone may cause or worsen depression 1, 3
• Obtain baseline liver function tests 1, 5
• Screen for opioid use disorder using DSM-5 criteria (requiring at least 2 criteria within a 12-month period) 1
• Assess for concurrent substance use, including alcohol and other drugs 1

---

Monitoring Requirements

Laboratory Monitoring

Liver function tests should be performed at baseline and every 3-6 months due to potential hepatotoxicity at supratherapeutic doses. 1, 5, 3

• Hepatotoxicity has not emerged as a clinical problem at the standard 50 mg dose, though at higher doses it is of concern 4
• For patients with alcoholic liver disease, liver function must be assessed before naltrexone injection 1

Clinical Monitoring

• Follow up at least monthly during treatment, with team members such as nurses, pharmacists, and behavioral health professionals providing support 1
• Assess treatment response after 12 weeks on maintenance dose (50 mg daily) 1
• Monitor for signs of depression, anxiety, or worsening mental health 1, 3
• Monitor for medication compliance using appropriate compliance-enhancing techniques 2

---

Adverse Effects

Common Side Effects

The most common side effects are nausea, constipation, headache, and gastrointestinal symptoms—generally mild and transient. 3

• Nausea is the most frequently reported adverse effect 4, 7
• Other mild and transient side effects include headache, dizziness, fatigue, and insomnia 6
• The tolerability of naltrexone is reasonable overall 4

Serious Adverse Effects

• Precipitated withdrawal: Most serious complication occurs when naltrexone is given to patients still dependent on opioids 7
• Hepatotoxicity: Occurs only at dosages much higher than the 50 mg per day recommended for treatment 7
• Depression and suicidality: Naltrexone may cause or worsen depression 1

Critical Safety Warning

Patients who discontinue naltrexone treatment have decreased opioid tolerance and are at increased risk of opioid overdose and death if they return to previous opioid use. 1, 5, 3

• Opioid overdose education and naloxone should be offered to patients discontinuing naltrexone 1, 3
• Patients must be educated about this increased sensitivity to opioids 1

---

Perioperative Management

Oral Naltrexone

Oral naltrexone should be held for 2-3 days prior to elective procedures if opioids are expected to be used perioperatively. 1, 3

Extended-Release Injectable Naltrexone

Extended-release naltrexone should be held for 24-30 days after the last injection before elective procedures. 1, 3

---

Discontinuation and Tapering

Tapering Protocol

For patients who have been on naltrexone long-term (≥1 year), tapers of 10% per month or slower are likely to be better tolerated than more rapid tapers. 1

• Each new dose should be 90% of the previous dose rather than a straight-line taper from the starting dose 1
• For short-term users, consider a moderate taper of 20-25% reduction per week 1
• Avoid abrupt discontinuation, which can precipitate withdrawal symptoms 1

Pre-Taper Assessment

• Assess for depression, anxiety, and insomnia before initiating taper, which should be addressed to improve taper outcomes 1
• Evaluate patient's motivation and readiness for tapering, as patient agreement and interest are key components of successful tapers 1

Monitoring During Taper

• Follow up frequently (at least monthly) with patients during the tapering process 1
• Monitor for signs of withdrawal, including anxiety, insomnia, abdominal pain, vomiting, diarrhea, diaphoresis, mydriasis, tremor, and tachycardia 1
• Clinically significant withdrawal symptoms signal the need to further slow the taper rate 1

Managing Withdrawal Symptoms

• Use of α2-adrenergic agonists (e.g., clonidine) is well-supported for managing withdrawal symptoms 1
• Symptomatic treatments, including nonsteroidal anti-inflammatory drugs or acetaminophen, can be helpful for managing muscle aches and pain 1
• Cognitive behavioral therapy and interdisciplinary approaches can support patients during tapering 1

---

Alternative and Complementary Therapies

For Alcohol Use Disorder

Alternative FDA-approved medications include disulfiram, acamprosate, and extended-release injectable naltrexone, with the choice depending on patient-specific factors and treatment goals. 8

• Disulfiram: Approved for increasing abstinence, works by causing unpleasant reactions when alcohol is consumed 8
• Acamprosate: Approved for increasing abstinence, particularly useful in patients with hepatic impairment where naltrexone is contraindicated 8, 1
• Baclofen: Alternative for patients with decompensated cirrhosis or acute hepatitis 1

For Opioid Use Disorder

Buprenorphine or methadone should be offered as first-line medication-assisted treatment for opioid use disorder, with naltrexone as an alternative for motivated patients preferring opioid-free treatment. 1

• Methadone: A mu-opioid receptor agonist designed for long-term opioid maintenance therapy 8
• Buprenorphine: A partial mu-opioid receptor agonist (mu agonist-kappa antagonist) with stronger evidence for preventing relapse 8, 1
• For pregnant women with opioid use disorder, buprenorphine (without naloxone) or methadone should be offered instead of naltrexone 1

Behavioral Therapies (Essential Component)

Naltrexone is only effective when combined with comprehensive psychosocial treatment, including counseling, group therapy, and support programs—medication alone is insufficient. 1, 5, 3

• Cognitive behavioral therapy and contingency management are the foundation of treatment for substance use disorders 5
• Naltrexone combined with cognitive coping skills therapy shows superior outcomes compared to supportive therapy alone 9
• Community-based support groups (e.g., Alcoholics Anonymous) are associated with good outcomes 2
• The addition of psychosocial care significantly reduces dropouts and rate of substance use during treatment and at follow-up 1

---

Clinical Algorithm for Patient Selection

Step 1: Confirm Diagnosis

• Verify DSM-5 criteria for alcohol use disorder or opioid use disorder (at least 2 criteria within 12-month period) 1

Step 2: Screen for Contraindications

• Confirm patient is opioid-free for minimum 7-10 days (short-acting) or up to 2 weeks (buprenorphine/methadone) 1, 3, 2
• Perform naloxone challenge test if any question of occult opioid dependence 2
• Rule out acute hepatitis, decompensated cirrhosis, pregnancy (for OUD), and current need for opioid pain management 1, 5, 3

Step 3: Assess Patient Motivation and Context

• For opioid use disorder: Naltrexone is most appropriate for highly motivated patients who prefer opioid-free treatment over methadone or buprenorphine maintenance 1, 3
• For alcohol use disorder: Assess for high-risk features such as difficulty identifying high-risk situations and external motivation for change 1
• Criminal justice populations show significant benefit from naltrexone treatment 1

Step 4: Baseline Testing

• Obtain liver function tests 1, 5
• Screen for depression, anxiety, and insomnia 1, 3
• Assess renal function if impairment suspected 1

Step 5: Initiate Treatment

• Start with 25 mg oral naltrexone to assess tolerance, then increase to 50 mg daily 2
• Alternatively, initiate with 380 mg monthly injectable if adherence is a concern 1, 3
• Ensure comprehensive psychosocial interventions are in place 1, 5, 3

Step 6: Monitor and Adjust

• Follow up at least monthly 1
• Monitor liver function tests every 3-6 months 1, 5
• Assess treatment response at 12 weeks 1
• Provide ongoing behavioral therapy and support 1, 5

---

Common Pitfalls and How to Avoid Them

Precipitated Withdrawal

• Pitfall: Starting naltrexone before patient is fully opioid-free 1, 3, 2
• Solution: Ensure minimum 7-10 day opioid-free period for short-acting opioids, up to 2 weeks for buprenorphine/methadone; perform naloxone challenge test if uncertain 2

Inadequate Psychosocial Support

• Pitfall: Prescribing naltrexone as monotherapy without comprehensive behavioral interventions 1, 5, 3
• Solution: Ensure patients are engaged in counseling, group therapy, or community support programs before initiating medication 1, 5

Failure to Educate About Overdose Risk

• Pitfall: Not warning patients about decreased opioid tolerance after discontinuation 1, 5, 3
• Solution: Provide opioid overdose education and offer naloxone to all patients, especially those discontinuing treatment 1, 3

Inappropriate Patient Selection

• Pitfall: Prescribing naltrexone to patients who need opioid pain management or are not motivated for treatment 1, 3
• Solution: Carefully assess patient's pain management needs and motivation; consider buprenorphine or methadone for less motivated patients with OUD 1

Inadequate Monitoring

• Pitfall: Failing to monitor liver function or mental health during treatment 1, 5
• Solution: Obtain baseline and periodic (every 3-6 months) liver function tests; screen for and monitor depression, anxiety, and suicidality 1, 5, 3

Perioperative Management Errors

• Pitfall: Not holding naltrexone before planned surgery requiring opioid analgesia 1, 3
• Solution: Hold oral naltrexone 2-3 days before elective procedures; hold extended-release naltrexone 24-30 days after last injection 1, 3

Concurrent Marijuana Use Concerns

• Pitfall: Withholding naltrexone from patients with concurrent marijuana use 1
• Solution: Naltrexone can be safely prescribed to patients with concurrent marijuana use, as there are no documented drug interactions or safety concerns between naltrexone and cannabis 1